StockData
COCHNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31Also trades as COCHW

Envoy Medical, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$0.65−0.01 (-2.10%)

Close on Oct 19, 2026

Market cap
$68.04M
P/E (TTM)
–
Dividend yield
–

About Envoy Medical

Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842

Envoy Medical, Inc. is a hearing health medical device company that develops implantable hearing technologies designed to utilize the natural anatomy of the ear. The company focuses on developing electrical and mechanical hearing systems across the hearing loss spectrum. Its key product development includes the Acclaim cochlear implant, a fully implanted investigational system featuring an implanted sensor, sound processor, and power source that captures sound without external, ear-worn components. The company also developed the Esteem fully implanted active middle ear implant. Its devices are designed for adult patients suffering from hearing loss, specifically targeting individuals with severe-to-profound sensorineural hearing loss who obtain limited benefit from conventional hearing aids.

The company operates in the medical device sector and conducts clinical trial activities in the United States, where approximately 1,000 of its middle ear devices have been implanted globally. Envoy Medical maintains its principal executive offices and headquarters in White Bear Lake, Minnesota.

Summary of the business section of Envoy Medical's latest annual report, written by StockData.

Company profile

Company

Legal name
Envoy Medical, Inc.
Headquarters
White Bear Lake, MN
Address
4875 White Bear Parkway 55110
Phone
(651) 361-8000
Employees
43, Dec 31, 2025
Industry
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Fiscal year ends
December 31
Auditor
GRANT THORNTON LLP, Fort Lauderdale, Florida

Stock & identifiers

Ticker
COCH
Other tickers
COCHW
Exchange
Nasdaq
IPO date
Mar 3, 2021
Shares outstanding
77M, Aug 10, 2026
Public float
$12.70M, Dec 31, 2025
Filer category
<br>Emerging growth company
SEC CIK
1840877
CUSIP
29415V109
ISIN
US29415V1098
EIN
86-1369123

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Brent T. LucasChief Executive Officer, Director342,666
Robert PotashnickCAO & VP of Finance212,500
Chas McKhannDirector–
Charles BrynelsenDirector1,050,000
Mona Chetan PatelDirector332,500
Susan KantorDirector174,037
Michael Curtis CroweDirector–
Janis Smith-GomezDirector–

Employees

Headcount reported in annual reports

“2025, we had approximately 43 full time employees and 4 part time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 22, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 31, 2026Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 27, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 25, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 28, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 29, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 3, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 14, 2023Late filingNotification of late filing
Oct 24, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 5, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Oct 5, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 29, 2023Name changeName changed from Anzu Special Acquisition Corp I to Envoy Medical, Inc.
Sep 29, 2023DelistingNotice of delisting from exchange (Form 25)
May 15, 2023MergerRegistration of securities for a merger or exchange offer (S-4)
Apr 3, 2023Late filingNotification of late filing
Aug 4, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 17, 2021Late filingNotification of late filing
Mar 3, 2021IPOInitial public offering priced (424B4 prospectus)
Mar 1, 2021ListingRegistration of securities on an exchange (Form 8-A)